technology
Commented by Fabian Lorenz on October 19th, 2026 | 05:35 CEST
Up 38% in One Week: OHB Takes Off - Could Nel ASA and First Hydrogen Be Next?
What a week for OHB shares. The stock surged by around 38%. This could mark the end of the sharp correction. Analysts see further upside for the German space company, citing its strong order backlog, which could expand further soon. Beyond space, robotics is another market of the future. Leading investment banks predict golden times for the sector. First Hydrogen aims to secure a share of the billions in expected revenue. If it succeeds, the stock is a strong candidate for a revaluation. Meanwhile, Nel shareholders were hoping for further gains at the start of last week. However, the Norwegian company's quarterly results quickly brought the rally to an end.
Read
Commented by Lars Winter on October 13th, 2026 | 05:22 CEST
BioNxt, CrowdStrike and Shell: Three exciting stocks ahead of the next price surge
On the stock market, facts matter most. New study results, strong figures and solid operational records tend to attract investor attention and often drive share prices higher. These three stocks deserve a closer look: BioNxt Solutions is approaching its first human study, CrowdStrike has reported a record quarter, and Shell is benefiting from exceptionally high refining margins. Three very different stocks, each offering opportunities alongside distinct risks. We take a closer look at these compelling names in our stock check.
Read
Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST
Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!
New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?
Read
Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST
BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk
The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.
Read
Commented by Carsten Mainitz on October 9th, 2026 | 09:05 CEST
Weight-Loss Drugs 2.0: Can BioNxt and Merck Catch Up with Novo Nordisk and Eli Lilly? What About BioNTech?
The boom in weight-loss drugs is creating a billion-dollar market within the pharmaceutical industry, with an annual volume of USD 100 billion. Novo Nordisk and Eli Lilly are battling for dominance, while Merck is also entering the fray, albeit still in the early stages. BioNxt Solutions aims to deliver established active ingredients via a dissolvable film, targeting enormous potential with a comparatively low-risk approach. For BioNTech, a substantial cash reserve will determine how much time the company has to deliver its next growth spurt. Where does the greatest stock-market opportunity lie?
Read
Commented by Fabian Lorenz on October 7th, 2026 | 08:35 CEST
Time to Sell Moderna Stock After a 200% Rally? A Comeback for Standard Lithium and HPQ Silicon?
Moderna's stock has had a spectacular run in recent weeks. Since mid-August, the biotech company's stock has surged from USD 63 to over USD 200. But now analysts are pouring cold water on the price surge. In their view, the stock could more than halve in value. While Moderna has already made a successful comeback, there are good reasons to believe that HPQ Silicon's is still to come. Despite positive news flow, the stock has yet to take off. Following successes in the drone sector, the company recently laid the groundwork to market its technology for producing fumed silica. Investors have been waiting for a comeback from Standard Lithium for quite some time. The stock is trading at a yearly low and approaching penny stock levels. Yet the company recently secured a new customer.
Read
Commented by Nico Popp on October 6th, 2026 | 07:35 CEST
Fighting Skin Cancer: How Vidac Pharma, Biofrontera and Regeneron Target Different Stages
At the recent annual meeting of the European Academy of Dermatology and Venereology in Vienna, the focus was on new approaches to treating extensive skin damage. The fight against skin cancer is shifting: It is no longer just about combating developed tumors, but about stopping the disease before it breaks out. Destroying diseased cells early on spares patients from major surgeries and eases the burden on the healthcare system. We present the latest developments and opportunities for investors.
Read
Commented by Nico Popp on October 2nd, 2026 | 09:50 CEST
Formycon and the Patent Cliff: Why Expiring Patents at Novartis and Merck Present an Opportunity for the German Biotech Industry
Even pharmaceutical giants are coming under pressure. The key term here is the patent cliff. According to industry estimates, between 2025 and 2030, active pharmaceutical ingredients with a global sales volume of approximately USD 300 billion will lose their exclusive patent protection. This turning point is forcing even pharmaceutical giants to rethink their strategies. Specialized developers will then bring biosimilars to market—equivalent and more affordable alternatives for healthcare systems. One well-known biosimilar provider is the German company Formycon. We examine the market and outline what makes Formycon's investment story compelling. But first, we look at two international pharmaceutical companies.
Read
Commented by Fabian Lorenz on October 2nd, 2026 | 06:55 CEST
BioNTech: A Setback or a Breakthrough? Micron and Volatus Aerospace Impress with Positive News Flow!
Contrarian investors, take note! An exciting opportunity may currently be emerging at Volatus Aerospace. Drone stocks continue to struggle on the stock market. However, the industry's long-term outlook remains positive in both the military and civilian sectors. While Volatus shares are consolidating, positive news continues to flow with new orders and technological advances. Micron Technology has also delivered strong news. Its record figures for 2026 exceeded estimates. The outlook is also positive. Can this dispel investors' skepticism regarding the sustainability of growth and margins? A sign of weakness or a bold move? This question arises with BioNTech in light of the permanent closure of three sites. The media response has been largely critical. However, there are also positive comments.
Read
Commented by Matthias Schomber on October 1st, 2026 | 07:55 CEST
Evotec, DroneShield and Power Metallic Mines: Turnaround Opportunities, Defence Boom and Commodities Hidden Gem
The stock market can be a madhouse at the best of times—and right now, some developments seem to defy all logic. Yet markets are rarely driven by fundamentals alone. Greed, fear and shifting investor sentiment can send stocks in directions that appear difficult to explain from a purely rational perspective. While the cards are being reshuffled at Evotec's modern laboratories following a management shakeup, DroneShield is looking to benefit from the new defence boom in the skies. In Canada, Power Metallic Mines sits on a vast polymetallic deposit. Each of the three stocks has its own technical chart setup. We examine the hard facts, look at margins and balance sheets, and assess the real opportunities. Which of these three stocks offers significant turnaround potential, and where do risks still loom? Read on to find out.
Read